Female, n (%)
|
11 (28.2)
|
Age (years)
|
63.23 ± 12.52
|
BMI (kg/m2)
|
23.81 ± 3.70
|
Diatbetes, n (%)
|
25 (64.1)
|
Diabetic nephritis as primary disease, n (%)
|
19 (48.7)
|
Nephrosclerosis, n (%)
|
5 (12.8)
|
PD vintage (months)
|
19.41 ± 21.73
|
D/P ratio
|
0.687 ± 0.143
|
D/D0 ratio
|
0.384 ± 0.106
|
Urinary volume (ml/day)
|
899.2 ± 452.8
|
Dialysate dose (ml/day)
|
5051.3 ± 1601.0
|
RASi, n (%)
|
28 (71.8)
|
Beta blocker, n (%)
|
9 (23.1)
|
Statin, n (%)
|
15 (38.5)
|
Diuretic (%)
|
30 (76.9)
|
Iron supplementation, n (%)
|
9 (23.1)
|
IVSd (mm)
|
9.795 ± 2.166
|
PWd (mm)
|
9.974 ± 2.194
|
LVDd (mm)
|
48.54 ± 7.181
|
LVDs (mm)
|
32.18 ± 7.904
|
LVMI (g/m2)
|
120.7 ± 38.99
|
EF (%)
|
61.62 ± 13.28
|
E/A
|
0.747 ± 0.250
|
Cardiac index
|
3.062 ± 1.334
|
Peritoneal Kt/V urea
|
4.825 ± 1.679
|
Renal Kt/V urea
|
3.816 ± 3.679
|
Weekly Kt/V urea
|
1.711 ± 0.757
|
Peritoneal CCr (L/week/1.73 m2)
|
3.623 ± 1.569
|
Renal CCr (L/week/1.73 m2)
|
5.771 ± 5.690
|
Weekly CCr (L/week/1.73 m2)
|
66.65 ± 34.43
|
Cr at starting PD (mg/dL)
|
7.368 ± 2.893
|
eGFR at starting PD (mL/ min/1.73 m2)
|
6.885 ± 2.293
|
ESA dose (μg/month)
|
127.3 ± 78.46
|
Plasma erythropoietin (mIU/mL)
|
7.933 ± 5.494
|
RBC (*104/μL)
|
360.7 ± 43.23
|
Hb (g/dL)
|
10.72 ± 1.266
|
Ht (%)
|
32.76 ± 3.805
|
Reticulocyte (‰)
|
10.33 ± 5.075
|
Fe (μg/dL)
|
88.18 ± 30.58
|
TIBC (μg/dL)
|
248.4 ± 41.77
|
Ferritin (ng/mL)
|
158.9 ± 153.4
|
TSAT
|
0.360 ± 0.133
|
CTR (%)
|
49.57 ± 5.435
|
NT-proBNP (pg/mL)
|
11839.8 ± 21293.2
|
Lactate (mg/dL)
|
10.85 ± 5.386
|
Ca (mg/dL)
|
8.438 ± 0.821
|
P (mg/dL)
|
5.818 ± 1.612
|
iPTH (pg/mL)
|
250.3 ± 117.4
|
Na (mEq/L)
|
138.8 ± 3.639
|
K (mEq/L)
|
4.564 ± 0.788
|
Cl (mEq/L)
|
101.6 ± 4.951
|
BUN (mg/dL)
|
62.20 ± 13.93
|
Cr (mg/dL)
|
9.591 ± 3.438
|
TP (g/dL)
|
6.241 ± 0.612
|
Alb (g/dL)
|
3.269 ± 0.404
|
CRP (mg/dL)
|
0.459 ± 2.144
|
sβ2MG (mg/L)
|
24.43 ± 9.657
|
Venous pH
|
7.360 ± 0.040
|
NYHA classification
|
I, n (%)
|
30 (76.9)
|
II, n (%)
|
9 (23.1)
|
III and IV
|
None
|